Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taurolidine Lock Solution for CRBSI Prevention in Hemodialysis
NCT07074821Phase 2Completed
- Sponsor
- Oman Ministry of Health
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of taurolidine in catheter-related bloodstream infection (CRBSI) (2 arms), sponsored by Oman Ministry of Health. Primary endpoint: Incidence of Catheter related blood stream infection at 1 year. Started Mar 2023; status: completed.
02
Drugs
taurolidine
03
Conditions
catheter-related bloodstream infection (CRBSI)
Beyond the preview
Go deeper on NCT07074821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074821.